Insider Selling: ChemoCentryx Inc (NASDAQ:CCXI) Major Shareholder Sells 88,012 Shares of Stock

ChemoCentryx Inc (NASDAQ:CCXI) major shareholder (International) Ltd Vifor sold 88,012 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $52.58, for a total transaction of $4,627,670.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

(International) Ltd Vifor also recently made the following trade(s):

  • On Monday, July 27th, (International) Ltd Vifor sold 34,236 shares of ChemoCentryx stock. The shares were sold at an average price of $53.32, for a total transaction of $1,825,463.52.
  • On Wednesday, July 22nd, (International) Ltd Vifor sold 72,469 shares of ChemoCentryx stock. The shares were sold at an average price of $55.58, for a total transaction of $4,027,827.02.
  • On Friday, July 24th, (International) Ltd Vifor sold 133,074 shares of ChemoCentryx stock. The shares were sold at an average price of $54.62, for a total transaction of $7,268,501.88.
  • On Monday, July 20th, (International) Ltd Vifor sold 54,598 shares of ChemoCentryx stock. The shares were sold at an average price of $56.03, for a total transaction of $3,059,125.94.
  • On Friday, July 17th, (International) Ltd Vifor sold 47,890 shares of ChemoCentryx stock. The shares were sold at an average price of $55.86, for a total transaction of $2,675,135.40.
  • On Wednesday, July 15th, (International) Ltd Vifor sold 86,298 shares of ChemoCentryx stock. The shares were sold at an average price of $59.22, for a total transaction of $5,110,567.56.
  • On Monday, July 13th, (International) Ltd Vifor sold 100,000 shares of ChemoCentryx stock. The stock was sold at an average price of $58.15, for a total transaction of $5,815,000.00.
  • On Friday, July 10th, (International) Ltd Vifor sold 45,844 shares of ChemoCentryx stock. The stock was sold at an average price of $59.92, for a total transaction of $2,746,972.48.
  • On Wednesday, July 8th, (International) Ltd Vifor sold 100,000 shares of ChemoCentryx stock. The stock was sold at an average price of $59.95, for a total transaction of $5,995,000.00.
  • On Monday, July 6th, (International) Ltd Vifor sold 86,690 shares of ChemoCentryx stock. The stock was sold at an average price of $58.44, for a total transaction of $5,066,163.60.

Shares of CCXI opened at $52.71 on Friday. ChemoCentryx Inc has a fifty-two week low of $6.16 and a fifty-two week high of $65.43. The firm’s 50 day moving average price is $57.54 and its 200 day moving average price is $50.31. The company has a quick ratio of 3.22, a current ratio of 3.22 and a debt-to-equity ratio of 0.40. The company has a market cap of $3.26 billion, a P/E ratio of -48.36 and a beta of 2.04.

ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.05). ChemoCentryx had a negative net margin of 192.93% and a negative return on equity of 100.55%. The firm had revenue of $6.01 million during the quarter, compared to analysts’ expectations of $8.90 million. Research analysts forecast that ChemoCentryx Inc will post -1.39 earnings per share for the current year.

Several large investors have recently made changes to their positions in CCXI. Sowell Financial Services LLC purchased a new stake in shares of ChemoCentryx in the 1st quarter valued at approximately $28,000. GQ Asset Management LLC purchased a new stake in shares of ChemoCentryx in the 1st quarter valued at approximately $46,000. Advisor Group Holdings Inc. purchased a new stake in shares of ChemoCentryx in the 1st quarter valued at approximately $47,000. Exane Derivatives purchased a new stake in shares of ChemoCentryx in the 1st quarter valued at approximately $86,000. Finally, Meeder Asset Management Inc. increased its position in shares of ChemoCentryx by 430.7% in the 1st quarter. Meeder Asset Management Inc. now owns 2,473 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 2,007 shares during the last quarter. 70.37% of the stock is currently owned by institutional investors.

Several equities analysts have recently commented on the stock. Canaccord Genuity restated a “buy” rating on shares of ChemoCentryx in a report on Wednesday, June 3rd. HC Wainwright restated a “buy” rating and issued a $69.00 price objective on shares of ChemoCentryx in a report on Monday, May 18th. JPMorgan Chase & Co. decreased their price objective on shares of ChemoCentryx from $64.00 to $61.00 and set an “overweight” rating on the stock in a report on Wednesday. Zacks Investment Research lowered shares of ChemoCentryx from a “buy” rating to a “hold” rating in a report on Friday. Finally, Piper Sandler upped their target price on shares of ChemoCentryx from $54.00 to $70.00 and gave the stock an “overweight” rating in a research note on Monday, May 18th. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. ChemoCentryx has an average rating of “Buy” and an average target price of $68.70.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy.

Featured Article: CBOE Russell 2000® Volatility Index

Insider Buying and Selling by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.